A microbiota-derived bile acid overcomes antibiotic-induced hyporesponsiveness to immune checkpoint therapy by enhancing CD8+ T cell antitumor immunity
Wenling Li, Christina M. Zarek, Hesuiyuan Wang, Shuheng Gan, Parastoo Sabaeifard, Priscilla Del Valle, Jiwoong Kim, Nicole A. Poulides, Laura Coughlin, Jake N. Lichterman, Cheng Cheng Zhang, Rebecca Suet-Yan Chiu, Tarun Srinivasan, Mauricio J. Velasquez, Indu Raman, , Andrew Young Koh
This study identifies TDCA, a microbiota-derived bile acid, as a mediator that restores immune checkpoint therapy efficacy after antibiotic-induced hyporesponsiveness by enhancing CD8+ T cell antitumor immunity.
bioRxiv · Apr 19, 2026 · PreprintCancer Biology